The US FDA has approved Johnson & Johnson's Spravato nasal spray as a standalone treatment for depression. It is the first-ever standalone therapy for treatment-resistant depression, a condition in which at least two standard treatments fail to significantly improve a patient’s symptoms. Previously, Spravato was cleared in the US to use together with an oral antidepressant.